CCB International logo

CCB International

Asia, Hong Kong Island, Hong Kong, Central

Description

CCB International (Holdings) Limited serves as the comprehensive investment services flagship of China Construction Bank Corporation, one of the world's largest commercial banks. Headquartered in Central, Hong Kong, CCB International leverages its powerful parentage to provide a wide array of financial services, including corporate finance and capital markets, asset management, wealth management, and critically, principal investments. This robust backing allows them to act as a significant and strategic investor across various stages and sectors, primarily within Greater China but with a growing global footprint.

The firm's principal investment arm is highly active in both private equity and venture capital, targeting high-growth companies with strong market potential. Their investment mandate spans a diverse range of sectors, including technology, media, and telecommunications (TMT), healthcare, advanced manufacturing, consumer goods, and financial technology. CCB International typically engages with companies from early-growth stages through to pre-IPO rounds, often taking a strategic minority stake. Their involvement frequently extends beyond capital, offering portfolio companies access to China Construction Bank's extensive network, resources, and market insights, which can be invaluable for expansion and market penetration.

CCB International is known for participating in substantial funding rounds, reflecting their capacity and strategic intent. For instance, they were a key investor in the $1.2 billion Series D round for AI giant SenseTime in 2018, demonstrating their ability to deploy significant capital into leading technology companies. While their investment sizes can vary widely depending on the stage and opportunity, their typical first cheque for venture and growth equity opportunities generally ranges from approximately $3 million for early-growth stage participation to upwards of $50 million for larger, more mature companies or pre-IPO rounds. Their extensive portfolio includes over 100 investments, underscoring their active role in the private markets.

Investor Profile

CCB International has backed more than 21 startups, with 4 new investments in the last 12 months alone. The firm has led 6 rounds, about 29% of its total and boasts 13 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series B, Series A rounds (top funding stages).
  • Majority of deals are located in China, United Kingdom, Singapore.
  • Strong thematic focus on Biotechnology, Health Care, Manufacturing.
  • Led 2 rounds in the past year.
  • Typical check size: $3M – $50M.

Stage Focus

  • Series C (38%)
  • Series B (14%)
  • Series A (14%)
  • Series D (10%)
  • Series Unknown (10%)
  • Series E (5%)
  • Private Equity (5%)
  • Debt Financing (5%)

Country Focus

  • China (86%)
  • United Kingdom (5%)
  • Singapore (5%)
  • Switzerland (5%)

Industry Focus

  • Biotechnology
  • Health Care
  • Manufacturing
  • Pharmaceutical
  • Automotive
  • Software
  • Artificial Intelligence (Ai)
  • Medical
  • Oncology
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does CCB International frequently co-invest with?

CICC
Asia, Beijing, China, Beijing
Co-Investments: 3
Goldman Sachs
North America, New York, United States, New York
Co-Investments: 2
CITIC Securities
Asia, Guangdong, China, Shenzhen
Co-Investments: 2
IDG Capital
Asia, Beijing, China, Beijing
Co-Investments: 3
Baidu Ventures
Asia, Beijing, China, Beijing
Co-Investments: 2
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 2
HongShan
Asia, Beijing, China, Beijing
Co-Investments: 3
Qiming Venture Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 3
Alibaba Health Information Technology
Asia, Beijing, China, Beijing
Co-Investments: 2
Shenzhen Capital Group
Asia, Hunan, China, Nanshan
Co-Investments: 4

What are some of recent deals done by CCB International?

Xinqiang Technology

Hangzhou, Zhejiang, China

Xinqiang Technology concentrates on delivering comprehensive digital solutions that encompass the entire technology stack.

AutomotiveElectronicsEnergyManufacturing
Series AMar 28, 2025
Amount Raised: $1,376,728
Syngenta Group

Basel, Basel-Stadt, Switzerland

Syngenta Group is a sustainable agricultural innovation and technology company.

AgricultureAgTechFarming
Debt FinancingDec 24, 2024
Amount Raised: $4,500,000,000
Galaxy Bot

Beijing, Beijing, China

Galaxy Bot is an innovative robotics company that provides intelligent universal service robotic products.

Intelligent SystemsManufacturingRobotics
Series UnknownNov 18, 2024
Amount Raised: $69,095,130
SINOGENE

Changping, Beijing, China

SINOGENE creates an animal gene editing and somatic cell cloning technology platform.

BiotechnologyGeneticsHealth CarePet
Series CSep 19, 2024
Amount Raised: $7,030,000
DJEL

Beijing, Beijing, China

DJEL is a semiconductor equipment and software company specializing in integrated circuit yield management.

ElectronicsManufacturingSemiconductorSoftware
Series UnknownNov 24, 2022
Amount Raised: $139,824,939
Origin Quantum

Hefei, Anhui, China

Origin Quantum is a full-stack quantum computing company that delivers a quantum computing cloud service platform.

Cloud ComputingHardwareInformation TechnologyQuantum Computing
Series BJul 22, 2022
Amount Raised: $148,119,621
SJ Semi

Jiangyin, Jiangsu, China

SJ Semi is a MEOL (Middle-End of Line) foundry that implements front-end wafer manufacturing and quality systems for MEOL operations.

IndustrialManufacturingSemiconductor
Series CMar 18, 2022
Amount Raised: $300,000,000
Mirxes

Singapore, Central Region, Singapore

Mirxes is an RNA technology company that develops blood-based miRNA test kits for early disease detection.

BiotechnologyHealth CareLife Science
Series CFeb 22, 2022
Amount Raised: $87,000,000
IASO Biotherapeutics

Nanjing, Jiangsu, China

IASO Biotherapeutics is a biopharmaceutical company focused on the development of cell therapies in the field of oncology.

BiotechnologyOncologyPharmaceutical
Series CSep 16, 2021
Amount Raised: $108,000,000
SVOLT

Changzhou, Zhejiang, China

SVOLT is an energy tech company that specializes in the manufacturing of automotive power batteries and energy storage systems.

BatteryEnergyEnergy StorageManufacturing
Series BAug 1, 2021
Amount Raised: $1,590,961,851